SCHOOL OF MEDICINE  |  PITT HOME  |  FIND PEOPLE  |  FIND A DOCTOR AT UPMC

Department of Medicine

Department of Medicine

  Division of Hematology/Oncology

[Return To Index page]
photo Frank S. Lieberman, MD

Chief-Adult Neuro-Oncology Service

Associate Professor-Neurology and Medical Oncology

Professor of Neurology

Email: liebermanf@upmc.edu

Phone: 412-692-2600

Contact
Office: UPMC Cancer Centers
5150 Centre Avenue, 5th Floor
Pittsburgh, PA 15232
 
Phone: 412-692-2600
Fax: 412-648-6579
E-mail: liebermanf@upmc.edu
Administrative Assistant:
Jana Parks
Address: 5150 Centre Avenue
5th floor
Pittsburgh, PA 15232
Email: parksjm2@upmc.edu
Phone: 412-692-2600
Education and Training
Education
BA, Franklin and Marshall College, 1975
MD, University of Chicago, 1979
Training
Intern-Medicine, University of Chicago Hospitals, 1980
Resident-Neurology, University of Chicago Hospitals, 1983
Research Fellow-Neuro-Immunology, University of Chicago, 1985
Research Interest
Dr. Lieberman serves as the director of the adult neuro-oncology program within the University of Pittsburgh Cancer Institute, where I oversee the design and conduct of clinical trials for patients with primary and metastatic brain tumors. I have over 30 years of experience in the design and conduct of translational therapeutic trials for brain tumor patients and current serve as our institutions principal investigator for participation in the Adult Brain Tumor Consortium, NRG Consortium, and ECOG-ACRIN. I currently serve on the CNS Tumor committee, experimental imaging, and biomarker committees for ECOG-ACRIN. I have a focused expertise and interest in immunotherapeutic approaches to high and low grade gliomas. I have served and currently serve as principal investigator as well as co-investigator in glioma vaccine trials as well immune checkpoint inhibitor trials and in trials evaluating molecularly targeted therapeutic drugs. I am currently co-investigator on our institutional imaging projects assessing novel PET tracers and high field strength MRI spectroscopy and dynamic contrast imaging as early biomarkers of response in clinical trials for newly diagnosed and recurrent glioblastomas. I served as chair of the working group for Clinical Trials Design and Development for the NCI Quantitative Imaging Network. In collaboration with Marina Nikaforovna and Ronald Hamilton in the Department of Pathology, I have participated in the development of one of the largest molecular genomic databases for high and low grade gliomas in the US.
Clinical Interest
Dr. Lieberman currently serve as the director of the adult neuro-oncology program within the UPMC Hillman Cancer Center , where I oversee the care of patients with primary and metastatic brain and spinal cord tumors as well as complications of cancer involving the nervous system. I have over 30 years of experience in the care of patients with central nervous system tumors. In addition to a large outpatient consultation practice focusing primary brain tumors, metastatic brain and spinal cord tumors, and the neurologic complications of cancer and its treatment, I direct the inpatient neurooncology consult services serving the inpatient solid tumor oncology, hematologic malignancy, and hematopoetic stem cell transplantation services at Shadyside as well as neurosurgical services at Shadyside and Presbyterian Hospitals. Within the brain tumor practice, I have focused interest and expertise in low grade and malignant gliomas, ependymomas, and tumors associated with neurofibromatosis 1 and 2. Within the neurologic complications of cancer practice, I have focused interest and expertise in the diagnosis and management of paraneoplastic neurologic disorders and in the neurocognitive side effects of radiation therapy and drug therapies for cancer.
Educational Interest
involved in resident and fellow teaching, supervising neurology and neurosurgery residents as well as hematology-oncology fellows. I oversee a combined inpatient and outpatient rotation in neurooncology for the neurology and neurosurgery residents and oversee hematology oncology fellows during the neurooncology component of the specialty clinic rotations. In addition I participate in neurology resident morning report, a teaching conference on the Oakland campus, and in neurology resident and hematology oncology journal clubs, and in the didactic conferences for both neurology and hematology- oncology trainees. I lecture in the Neoplasia course for 4th year students and serve as a facilitator in the 2nd year neuroscience course for medical students. At the national level, I am a member of the committee which wrote the first neurooncology subspecialty board examination for the UCNS, and currently serve on the committee revising the exam for 2017.
Publications
For my complete bibliography, Click Here.
Selected Publications:
Okada H, Butterfield LH, Hamilton FL, Hoji A, Sakaki M, Ahn BJ, Kohanbash G, Drappatz J, Engh J, Amankulor N, Lively MO, Chan MD, Salazar AM, Shaw EG, Potter DM, Lieberman FS. Induction of robust type-I CD8+ T-cell responses in WHO grade 2 low-grade glioma patients receiving peptide-based vaccines in combination with poly-ICLC. Clinical Cancer Research. 2014; 21(2): 286-294.
Qian Y, Panigrahy A, Laymon CM, Lee VK, Drappatz J, Lieberman FS, Boada FE, Mountz JM. Short-T2 imaging for quantifying concentration of sodium (23 Na) of bi-exponential T2 relaxation. Magnetic Resonance in Medicine. 2014; E ahead of print.
Oborski MJ, Laymon CM, Qian Y, Lieberman FS, Nelson AD, Mountz JM. Challenges and Approaches to Quantitative Therapy Response Assessment in Glioblastoma Multiforme Using the Novel Apoptosis Positron Emission Tomography Tracer F-18 ML-10. Translational Oncology. 2014; 7(1): 111-9.
Wong ET, Lok E, Swanson KD, Gautam S, Engelhard HH, Lieberman F, Taillibert S, Ram Z, Villano JL. Response assessment of NovoTTF-100A versus best physician's choice chemotherapy in recurrent glioblastoma. Cancer Medicine. 2014; 3: 592-602.
Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro-oncology. 2014; 16(4): 567-78.
Imani F, Boada FE, Lieberman FS, Davis DK, Mountz JM. Molecular and metabolic pattern classification for detection of brain glioma progression. European Journal of Radiology. 2013; 83(2): 100-5.
Kurland BF, Gerstner ER, Mountz JM, Schwartz LH, Ryan CW, Graham MM, Buatti JM, Fennessy FM, Eikman EA, Kumar V, Forster KM, Wahl RL, Lieberman FS. Promise and pitfalls of quantitative imaging in oncology clinical trials. Magnetic Resonance Imaging. 2012; 30(9): 1301-12.
Okada H, Kalinski P, Ueda R, Hoji A, Kohanbash G, Donegan TE, Mintz AH, Engh JA, Bartlett DL, Brown CK, Weh H, Holtzman MP, Reinhart TA, Whiteside TL, Butterfield LH, Hamilton RL, Potter DM, Pollack IF, Salazar AM, Lieberman FS. Induction of CD8+ T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with {alpha}-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. Journal of Clinical Oncology. 2011; 29(3): 330-6.